Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
NHS Blood and Transplant (NHSBT) is a Special Health Authority and is responsible for the provision of blood components and a range of associated laboratory and patient therapeutic services to hospitals. The NHSBT Therapeutic Apheresis Service (TAS) provide lifesaving and life-enhancing therapies to adults and children across a range of clinical specialties. Patients receive treatment either at their hospital bedside or where clinically appropriate as an outpatient in an NHS Blood and Transplant (NHSBT) unit. NHSBT provides regional access to apheresis services from 10 dedicated units across England and Wales (Bristol, London, Oxford, Leeds, Sheffield, Liverpool, Manchester, Birmingham, Plymouth, Cambridge and Liverpool) with each unit led by a team of specialist medical and nursing staff. Prior to commencing a formal procurement process and to help inform strategy requirements, NHSBT would like to consult the market to establish the level of interest for the purchase of therapeutic apheresis machines, consumables and maintenance, to support provision of new Therapeutic Apheresis Systems for Extracorporeal Photopheresis (ECP), Apheresis Collection, Exchange and Depletion Procedures (including Bone Marrow), and associated consumables and maintenance. Requirements also include consumables, maintenance and repair of existing NHSBT owned Cellex ECP Machines and Optia Multi-Apheresis Machines.
No supplier information available.
This procurement was divided into 2 lots, each awarded separately.
| Lot | Value | Status |
|---|---|---|
| Lot 1 Multi-Apheresis Systems Feb 2027 – Jan 2035 | £26,800,000 | active |
| Lot 2 ECP Systems Feb 2027 – Jan 2035 | £20,600,000 | active |
Weightings from the notice, applied to every lot.